A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and tolerability of escalating doses of BP1002 (Liposomal
Bcl-2 Antisense Oligodeoxynucleotide) in patients with refractory/relapsed AML. The study is
designed to assess the safety profile, identify DLTs, biologically effective doses, PK, PD
and potential anti-leukemic effects of BP1002 as single agent (dose escalation phase)
followed by assessing BP1002 in combination with decitabine (dose expansion phase).